Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer

Published:2021-12 Issue: Volume:123 Page:105589
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Cabezas-Camarero Santiago,Alonso-Ovies Almudena,Merino-Menéndez Salomé,Cabrera-Martín María Nieves,Plaza-Hernández José Carlos,Pérez-Segura Pedro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference16 articles.

1. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial;Uppaluri;Clin Cancer Res,2020

2. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial;Schoenfeld;JAMA Oncol.,2020

3. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial;Ferris;J Immunother Cancer,2021

4. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC);de Ruiter;Mod Pathol,2021

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review;Oral Oncology Reports;2024-09

2. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

3. Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?;Critical Reviews in Oncology/Hematology;2023-06

4. Safety and preliminary activity of pembrolizumab‑carboplatin‑paclitaxel in heavily pretreated and/or fragile patients with PDL1‑positive recurrent/metastatic head and neck cancer;Oncology Letters;2022-12-07

5. Carboplatin/paclitaxel/pembrolizumab;Reactions Weekly;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3